An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria

被引:0
作者
Peter Bramlage
Stefanie Lanzinger
Steffen Mühldorfer
Karsten Milek
Anton Gillessen
Roman Veith
Tobias Ohde
Thomas Danne
Reinhard W. Holl
Jochen Seufert
机构
[1] Institute for Pharmacology and Preventive Medicine,Institut für Epidemiologie und medizinische Biometrie
[2] ZIBMT; Universität Ulm,Innere Medizin
[3] Deutsches Zentrum für Diabetesforschung e.V.,Nephrologie
[4] Darm-Und Pankreaskarzinomzentrum,Kinderkrankenhaus auf der Bult
[5] Diabetologische Schwerpunktpraxis,Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II
[6] Herz-Jesu-Krankenhaus,undefined
[7] Klinikum Bad Hersfeld,undefined
[8] Diabeteszentrum Essen-Nord,undefined
[9] Diabeteszentrum für Kinder und Jugendliche,undefined
[10] Universitätsklinikum Freiburg,undefined
来源
Cardiovascular Diabetology | / 22卷
关键词
Diabetes; Diabetic kidney disease; Hypertension; Chronic kidney disease; Glomerular filtration rate; Albuminuria; Diagnostics; Pharmacotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 323 条
  • [1] Xie Y(2018)Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016 Kidney Int 94 567-581
  • [2] Bowe B(2016)Diabetic kidney disease: world wide difference of prevalence and risk factors J Nephropharmacol 5 49-56
  • [3] Mokdad AH(2014)Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on kidney disease: improving global outcomes (KDIGO) staging BMC Res Notes 7 415-2045
  • [4] Xian H(2017)Diabetic kidney disease: challenges, progress, and possibilities Clin J Am Soc Nephrol 12 2032-297
  • [5] Yan Y(2016)The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review PLoS ONE 11 e0147329-377
  • [6] Li T(2018)The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes J Diabetes Complicat 32 291-869
  • [7] Maddukuri G(2018)CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease Nat Rev Nephrol 14 361-860
  • [8] Tsai CY(2001)Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861-591
  • [9] Floyd T(2001)Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851-1462
  • [10] Al-Aly Z(2008)Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580-323